skip to main content

ProfessionalsCrystal L. Parker

Crystal L. Parker

Tel: +1-212-373-3069
Fax: +1-212-492-0069

New York

1285 Avenue of the Americas
New York, NY 10019-6064
Fax: +1-212-492-0069

Bar Admissions 
Bar Admissions 

A partner in the Litigation Department and Deputy Chair of the Patent Litigation Group, Crystal Parker focuses her practice on patent litigation matters involving a wide range of technology sectors, with a particular emphasis on Hatch-Waxman litigation, biologics and medical devices. Crystal has also represented clients in breach of contract, false advertising, trademark and products liability litigation, as well as in arbitration proceedings.

Crystal has litigated cases in key patent jurisdictions, including Delaware, New Jersey, Massachusetts, the U.S. Court of Appeals for the Federal Circuit and the International Trade Commission. She has experience in all phases of litigation, from pre-suit investigations through fact and expert discovery, dispositive motions, trial and appeal.


Her representative cases include: 

  • AbbVie in multiple bellwether trials in federal and state court related to the company’s testosterone replacement therapy product, including securing a complete defense verdict at trial in Illinois state court;  
  • Chugai Pharmaceutical in a pair of inter partes review (IPR) victories against a major pharmaceutical company, defending two of Chugai’s patents for a new, simpler and less costly method of removing DNA contaminants from proteins, a key step in the production of genetically engineered and biologic drugs;
  • Genentech Inc. in litigations involving the anti-PD-L1 antibody TECENTRIQ® (atezolizumab), and Hatch-Waxman litigation regarding the cancer treatment ALECENSA® (alectinib);
  • IBM in connection with several actual and threatened trade secrets litigations concerning the enforcement of employee-restrictive covenants and non-competition agreements; and
  • A major biotechnology company in a significant IPR win at the Patent Trial and Appeal Board (PTAB). The proceeding sought to invalidate a patent for a rheumatoid arthritis treatment, but in a final written decision, the Board found that the challenger, a major pharmaceutical company with a proposed biosimilar product, had failed to show any of the challenged claims to be unpatentable.

© 2023 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy